medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2020, Number 3

<< Back Next >>

Acta Med 2020; 18 (3)

Statin intolerance and myopathy

Ariza AR, Halabe CJ, Lifshitz GA

Language: Spanish
References: 26
Page: 290-295
PDF size: 179.60 Kb.


ABSTRACT

Adverse events due to statin’s administration are mainly confined to the musculoskeletal system. The different manifestations include nocebo effects, myalgias, muscular atrophy, myositis, and rarely rhabdomyolisis. Several etiopathogenic mechanisms are involved, but, individual susceptibility and multiple morbility are of major importance. Now a days there are strategies for their prevention and treatment, and, in cases of true actual intolerance or serious adverse events, alternative mechanisms to reduce c-LDL are available. Statins are one of the most widely used drugs in modern medicine and as such, it is important to recognize their adverse events in order to prevent them and to make and early diagnosis and treatment.


REFERENCES

  1. Mehta JL. Statins: understanding clinical use. Philadelphia, USA: Elsevier Inc; 2004.

  2. Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389.

  3. Pencina MJ, Navar-Boggan AM, D’Agostino RB, Williams K, Neely B, Sniderman AD et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014; 370: 1422-1431.

  4. INSP. Encuesta Nacional de Salud y Nutrición 2018. Disponible en: ensanut.insp.mx.

  5. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002; 346: 539-540.

  6. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolisis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990; 264: 71-75.

  7. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. JACC. 2002; 40: 567-572.

  8. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol. 2006; 97 [Suppl]: 89C-94C.

  9. Rosenson RS, Baker S, Jacobson TA, Kopecky SL, Parker BA. An assessment by statin muscle safety task force: 2014 update. J Clin Lipidiol. 2014; 8: S58-S71.

  10. Toth PP, Patti AM, Giglio RM, Nikolic D, Castellino G, RizzoM, Banach M. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018; 18: 157-173.

  11. Ward NC, Watts GF, Eckel RH. Statin toxicity. Mechanistic insights and clinical implications. Cir Res. 2019; 124: 328-350.

  12. Ariza AR. El efecto nocebo: los problemas actuales de la información no regulada. Acta Med GA (Mex). 2019; 17: 205-206.

  13. Rosenson RS, Baker S, Banache M, Borow KM, Braun LT, Bruckert E et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017; 70: 1290-1301.

  14. Thompson PD, Clarkson PM, Rosenson RS. National lipid association statin safety task force muscle safety expert panel. An assessment of statin safety by muscle experts. Am J Cardiol. 2006; 97: 69C-76C.

  15. Baker SK, Tarnopolsky. Statin myopathies pathophysiologic and clinical perspectives. Clin Invest Med. 2001; 24: 258-272.

  16. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin associated myopathy. A systematic review. J Am Coll Cardiol. 2007; 49: 2231-2237.

  17. Phillips PS, Haas RH, Bannykh S, Hathaway S, Nancy RN, Gray L, Kimura BJ et al. Statin-Associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002; 137: 581-585.

  18. Thompson P, Clarkson P, Karas RH. Statin-Associated myopathy. JAMA. 2003; 289: 1681-1690.

  19. Thoth PP, Harper CHR, Jacobson TA. Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev Cardiovasc Ther. 2008; 6: 955-999.

  20. Hanai JI, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest. 2207; 117: 3940-3951.

  21. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007; 17 (2): 194-200.

  22. Mammen AL. Statin-associated autoinmune myopathy. N Engl J Med. 2016; 374: 664-669.

  23. Nazir S, Lohani S, Tachamo N, Poudel D, Donato A. Statin-associated autoimmune myopathy. A systematic review of 100 cases. J Clin Rheumatol. 2017; 23: 149-153.

  24. Gatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Aterosclerosis. 2010; 210: 337-343.

  25. The SEARCH Collaborative Group: SLC01B1 variants and statin induced myopathy-A genomewide study. N Engl J Med. 2008; 359: 789-799.

  26. Kansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in patients with statin-associated myopathy. Arch Intern Med. 2005; 165: 2.




2020     |     www.medigraphic.com